<SEC-DOCUMENT>0001213900-24-090982.txt : 20241028
<SEC-HEADER>0001213900-24-090982.hdr.sgml : 20241028
<ACCEPTANCE-DATETIME>20241028083510
ACCESSION NUMBER:		0001213900-24-090982
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241028
FILED AS OF DATE:		20241028
DATE AS OF CHANGE:		20241028

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroSense Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001875091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41084
		FILM NUMBER:		241398536

	BUSINESS ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
		BUSINESS PHONE:		972-9-9531142

	MAIL ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0218396-6k_neurosense.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer<BR>
Pursuant to Rule&nbsp;13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the Month of October 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: 001-41084</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NeuroSense Therapeutics Ltd.<BR>
</B>(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NeuroSense Therapeutics Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>11 HaMenofim Street, Building B<BR>
Herzliya 4672562 Israel<BR>
+972-9- 7996183<BR>
</B>(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form&nbsp;20-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>INFORMATION CONTAINED
IN THIS REPORT ON FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On October 28, 2024, NeuroSense Therapeutics Ltd.
(the &ldquo;Company&rdquo;) issued a press release entitled &ldquo;NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial
and NDA Submission.&rdquo; A copy of the press release is filed herewith as&nbsp;Exhibit 99.1.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Report on Form 6-K and the first paragraph
of the press release attached as Exhibit 99.1 are hereby incorporated by reference into the registrant&rsquo;s Registration Statements
on Form S-8&nbsp;(File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390022005072/ea154846-s8_neurosense.htm">333-262480</A>) and&nbsp;Form&nbsp;F-3&nbsp;(File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390023003838/ea171892-f3_neurosense.htm">333-269306</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024030451/ea0203321-posam_neurosense.htm">333-260338</A>), to be a part thereof from the
date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 9%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B>&nbsp;<B>No.</B></FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea021839601ex99-1_neuro.htm">Press Release, dated October 28, 2024, entitled &ldquo;NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission.&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>NeuroSense Therapeutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: October 28, 2024</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Alon Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Alon Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Office</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea021839601ex99-1_neuro.htm
<DESCRIPTION>PRESS RELEASE, DATED OCTOBER 28, 2024, ENTITLED "NEUROSENSE SECURES KEY FDA MEETING TO ADVANCE ITS PHASE 3 ALS TRIAL AND NDA SUBMISSION."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 68px; width: 200px"></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroSense Secures Key FDA Meeting to Advance
its Phase 3 ALS Trial and NDA Submission</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-size: 12pt">Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory
path for submission based on trial success </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-size: 12pt">Parallel preparations in Canada: NeuroSense plans to submit its dossier in Q2 2025, with a regulatory
decision on commercialization expected by Q1 2026</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">CAMBRIDGE, Mass., </FONT>October
28, 2024, <FONT STYLE="background-color: white">-- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (&ldquo;NeuroSense&rdquo;), a late-clinical
stage biotechnology company </FONT>developing novel treatments for severe neurodegenerative diseases, today announced it is scheduled
for a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss the design of its upcoming Phase 3 clinical trial for
PrimeC, a potential treatment for Amyotrophic Lateral Sclerosis (ALS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA Type C meeting, scheduled for November 6, 2024, will focus
on finalizing the design of the Phase 3 trial, a pivotal step toward securing approval for the drug. NeuroSense will also review its readiness
for a future New Drug Application (NDA) submission, ensuring its regulatory strategy aligns with the FDA&rsquo;s requirements. NeuroSense
plans to give an update on the results of the meeting following receipt of the meeting minutes which are expected approximately one month
after the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PrimeC, NeuroSense&rsquo;s lead product, has shown promising results
in clinical trials, including a statistically significant reduction in disease progression clinical and biological markers. With an urgent
unmet need in ALS, NeuroSense is positioning PrimeC as a potential breakthrough therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In parallel, <FONT STYLE="font-size: 10pt; background-color: white">NeuroSense
plans to submit its regulatory dossier to Health Canada in Q2 2025, with a regulatory decision anticipated by Q1 2026. The Company estimates
the potential market opportunity for PrimeC in Canada alone to be approximately $100 million to $150 million in annual revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">This decision follows the recommendations
of Canadian regulatory experts and recent clinical findings, which demonstrated that PrimeC significantly reduced disease progression
(p=0.009) and improved survival rates by 43% compared to placebo, highlighting its potential as a breakthrough therapy for ALS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>About
ALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">Amyotrophic
lateral sclerosis (&ldquo;ALS&rdquo;) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years
from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of&nbsp;$1
billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 68px; width: 200px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>About
ALSFRS-R</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Disease progression is measured by the ALS Functional
Rating Scale-Revised (ALSFRS-R), which is the most widely used ALS tracking tool accepted by the FDA, utilized by neurologists treating
ALS patients, in clinical trials, and by other regulators to determine disease progression. It tracks 12 changes in a person&rsquo;s physical
abilities over time including functions such as: speech, walking, climbing stairs, dressing/hygiene, handwriting, turning in bed, cutting
food, salivation, swallowing, and breathing. A single point change on the ALSFRS-R has a significant impact on ALS patients, such as the
transition from independent feeding to requiring assistance or independent breathing to needing to use a machine ventilator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white"><B>About
PARADIGM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">PARADIGM
is a prospective, multinational, randomized, double-blind, placebo-controlled Phase 2b (NCT05357950) clinical trial of PrimeC in ALS.
The trial included 68 participants living with ALS in Canada, Italy, and Israel. 96% of the trial participants who completed the 6-month
double-blind portion of the trial chose to receive treatment with PrimeC through a 12-month open label extension. Furthermore, to date
(June 2024) all participants that completed the 18-month trial treatment duration, requested to continue PrimeC, which is provided to
them in an Investigator Initiated Trial, not limited with time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">As previously
reported, in the 6-month double-blind segment of the trial, the data showed clinically meaningful signs of efficacy with a 29% difference
in favor of PrimeC vs placebo in analysis of the intent to treat (ITT) population. In the PP top-line analysis</FONT> from PARADIGM, a
statistically significant slowing of disease progression was observed with a 37.4% (p=0.03) difference in ALSFRS-R in favor of PrimeC
vs placebo. <FONT STYLE="background-color: white">Most patients enrolled in both the active and placebo arms of the trial were concurrently
treated with Riluzole, the ALS standard of care medication, indicating PrimeC slowed disease progression well beyond the level afforded
by the FDA approved ALS drug.&nbsp; &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white"><B>About
PrimeC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">PrimeC,
NeuroSense&rsquo;s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved
drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS that contribute to motor
neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (&ldquo;RNA&rdquo;) regulation to potentially inhibit
the progression of ALS. NeuroSense completed a Phase 2a clinical trial which met its safety and efficacy endpoints including reducing
functional and respiratory deterioration and statistically significant changes in ALS-related biological markers indicating PrimeC&rsquo;s biological
activity. PrimeC was granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>About
NeuroSense</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">NeuroSense
Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from
debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include </FONT>amyotrophic lateral sclerosis <FONT STYLE="background-color: white">(ALS),
Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease, among others, represent one of the most significant unmet medical needs of our time, with
limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on
strong scientific research on a large panel of related biomarkers, NeuroSense&rsquo;s strategy is to develop combined therapies targeting multiple
pathways associated with these diseases. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">For additional
information, we invite you to visit our&nbsp;website&nbsp;and follow us on&nbsp;LinkedIn, YouTube&nbsp;and&nbsp;X. Information that may
be important to investors may be routinely posted on our website and these social media channels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 68px; width: 200px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white"><B>Forward-Looking
Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">This press
release contains &ldquo;forward-looking statements&rdquo; that are subject to substantial risks and uncertainties. All statements, other
than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained
in this press release may be identified by the use of words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo;
&ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;seek,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo;
&ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;target,&rdquo; &ldquo;aim,&rdquo; &ldquo;should,&rdquo;
&ldquo;will&rdquo; &ldquo;would,&rdquo; or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics&rsquo; current expectations and are subject
to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory
filings and regulatory decisions, the market opportunity in Canada and securing regulatory approval in global markets. Further, certain
forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends
may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements.
These risks include the risk of a delay in submission by the Company of its regulatory dossier, that regulatory approvals for PrimeC will
be delayed or not obtained in Canada or elsewhere; that the market opportunity in Canada will not be as currently estimated; unexpected
R&amp;D costs or operating expenses, insufficient capital to complete development of PrimeC, a delay in the reporting of additional results
from PARADIGM clinical trial, the timing of expected regulatory and business milestones, risks associated with meeting with the FDA and
Health Canada to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such meeting;
the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes
and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of any product
candidates of Neurosense; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense&rsquo;s
filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future.
More information about the risks and uncertainties affecting NeuroSense is contained under the heading &ldquo;Risk Factors&rdquo; in the
Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2024 and NeuroSense&rsquo;s subsequent filings
with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to
update such information except as required under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">For further
information: Email: info@neurosense-tx.com, Tel: +972 (0)9 799 6183</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !- .,# 2(  A$! Q$!_\0
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M7P6^&VGP-K.L2R,LEY-!#<31VVF:<D\L\MSJ=_,$>1)\&5XYBE/P+^V&E_\
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M%=;FWD1)(W9DK>//^"A/PY\$?'GPK^S^WP_^)=]XH\2^/],\ ?VQ>:+'X?\
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M0O#X<\6Z-/'9>(M'62,+)!'<O%-#=V$LJ1W$NGWD,UN9XUEB$4I9SY;\#?\
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M1E'#V?PS/'X3&<1YW5Q>,Q.)Q^3T<-DM/+LNKX[*UB:+S"IB8X:-'!TO/K>
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M@*DHT<50YUSTI<U+$X6JW6PF*P]5R=7\Z\3?"K@CQ>X<GPSQQE$<QP4:CQ.
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M^RS+*,1PKF"Q"AB%S5TF?F1\>/B)^WY\;K>T;3/'NH_%_P"''B6X@T[3[_\
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M RS+LLPU'"8/+\'AZ:IT*&$PU&$:-*G2BKQ2C)RFYU*DJM6I5JU?R[F_:/\
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MYU$GS345)W;NH)J.C;2LFUHEN[W"BBBI+"BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
